Nakanishi Inc.

7716.T
Medical Instruments & Supplies
2026/03/05 Updated
Market Cap: $1.4B (¥215.3B)
Stock Price: $16.44 (¥2,593)
Exchange Rate: 1 USD = ¥157.73

Notice Regarding Revision of Earnings Guidance for the Second Quarter and Full Year Ending December 2026

The earnings guidance for the second quarter and full year ending December 2026 has been revised upward by 1.5% and 2.3% in net sales respectively. Interim net income attributable to owners of parent is revised to 5,308 million yen (1.2% increase) for Q2 and 11,193 million yen (2.3% increase) for the full year.

Importance:
Page Updated: March 5, 2026
IR Disclosure Date: March 5, 2026

Key Figures

  • Q2 Net Sales: 44,374 million yen (vs. previous forecast +1.5%)
  • Q2 Interim Net Income Attributable to Owners of Parent: 5,308 million yen (vs. previous forecast +1.2%)
  • Full Year Net Sales: 90,185 million yen (vs. previous forecast +2.3%)
  • Full Year Net Income Attributable to Owners of Parent: 11,193 million yen (vs. previous forecast +2.3%)
  • Performance contribution period due to subsidiary acquisition: April to December 2026

AI要約

Details of the Earnings Guidance Revision

Nakanishi Inc. has revised upward its earnings guidance for the second quarter and full year ending December 2026. Second quarter net sales increased by 1.5% from the previous forecast of 43,734 million yen to 44,374 million yen, and interim net income attributable to owners of parent increased by 1.2% from 5,246 million yen to 5,308 million yen. For the full year, net sales rose 2.3% from 88,180 million yen to 90,185 million yen, and net income increased 2.3% from 10,943 million yen to 11,193 million yen. These revisions primarily reflect the consolidation of performance following the subsidiary acquisition of U.S. medical device manufacturers Acra Cut and Intech.

Outlook and Assumptions

The exchange rate assumptions underlying the earnings guidance remain unchanged at 150 yen per 1 US dollar and 170 yen per 1 euro. Going forward, it is necessary to continue reflecting the subsidiaries’ performance in consolidated results and carefully monitor factors influencing business performance fluctuations. Note that the forecast figures are based on currently available information and actual results may differ due to various factors.

Comparison of Net Sales Guidance for Q2 and Full Year Ending December 2026

Comparison of Net Income Attributable to Owners of Parent Guidance for Q2 and Full Year Ending December 2026

This page uses AI to summarize IR materials from TDnet. Please refer to the original document for investment decisions.